EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

The role of aberrant DNA methylation in cancer initiation and clinical impacts

Franziska Geissler iD, Ksenija Nesic iD, Olga Kondrashova, Alexander Dobrovic, Elizabeth M Swisher, Clare L Scott, Matthew J Wakefield iD

Therapeutic Advances in Medical Oncology · 2024-01 · 16

DOI: 10.1177/17588359231220511 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 28.01.2024. Verfasst von Franziska Geissler und 6 weiteren Autor:innen. Beteiligte Einrichtung: Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia. Die Arbeit wurde bisher 102-mal zitiert (Crossref) und nennt 198 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, National Health and Medical Research Council, Swiss Cancer Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epigenetic alterations, including aberrant DNA methylation, are now recognized as bone fide hallmarks of cancer, which can contribute to cancer initiation, progression, therapy responses and therapy resistance. Methylation of gene promoters can have a range of impacts on cancer risk, clinical stratification and therapeutic outcomes. We provide several important examples of genes, which can be silenced or activated by promoter methylation and highlight their clinical implications. These include the mismatch DNA repair genes MLH1 and MSH2, homologous recombination DNA repair genes BRCA1 and RAD51C, the TERT oncogene and genes within the P15/P16/RB1/E2F tumour suppressor axis. We also discuss how these methylation changes might occur in the first place – whether in the context of the CpG island methylator phenotype or constitutional DNA methylation. The choice of assay used to measure methylation can have a significant impact on interpretation of methylation states, and some examples where this can influence clinical decision-making are presented. Aberrant DNA methylation patterns in circulating tumour DNA (ctDNA) are also showing great promise in the context of non-invasive cancer detection and monitoring using liquid biopsies; however, caution must be taken in interpreting these results in cases where constitutional methylation may be present. Thus, this review aims to provide researchers and clinicians with a comprehensive summary of this broad, but important subject, illustrating the potentials and pitfalls of assessing aberrant DNA methylation in cancer.

Schlagwörter

Stichwörter der Autor:innen

BRCA-related cancersdiagnosisepigenomicsgenomic testinggenomicshomologous recombination deficiencyoncogenic driver mutationstargeted therapytherapeutic resistance

Autor:innen und Institutionen

  • Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.
  • Department of Medical Biology, University of Melbourne, Parkville, VIC, Australia.
  • QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
  • University of Melbourne Department of Surgery, Austin Health, Heidelberg, VIC, Australia.
  • University of Washington, Seattle, WA, USA.
  • Department of Obstetrics and Gynaecology, University of Melbourne, Parkville, VIC, Australia.

ORCID-Profile: Franziska Geissler, Ksenija Nesic, Matthew J Wakefield

Förderung

  • NCI NIH HHS
  • National Health and Medical Research Council
  • Swiss Cancer Research Foundation
  • NIH NCI

Zitieren

APA

Geissler, F., Nesic, K., Kondrashova, O., Dobrovic, A., Swisher, E. M., Scott, C. L., & J Wakefield, M. (2024). The role of aberrant DNA methylation in cancer initiation and clinical impacts. Therapeutic Advances in Medical Oncology, 16. https://doi.org/10.1177/17588359231220511

Vancouver

Geissler F, Nesic K, Kondrashova O, Dobrovic A, Swisher EM, Scott CL, et al. The role of aberrant DNA methylation in cancer initiation and clinical impacts. Therapeutic Advances in Medical Oncology. 2024;16. doi:10.1177/17588359231220511

BibTeX
@article{Geissler2024,
  author = {Geissler, Franziska and Nesic, Ksenija and Kondrashova, Olga and Dobrovic, Alexander and Swisher, Elizabeth M and Scott, Clare L and J Wakefield, Matthew},
  title = {The role of aberrant DNA methylation in cancer initiation and clinical impacts},
  journal = {Therapeutic Advances in Medical Oncology},
  year = {2024},
  volume = {16},
  doi = {10.1177/17588359231220511}
}
Kostenlos starten →